Our goal is to address serious medical conditions, across multiple and diverse therapeutic areas. Our FDA-approved medicines are only the beginning of our long-term commitment to solve the human body's most complex mysteries.
In addition to our work to invent new and needed medicines, we are focused on improving our world and operating with the highest standards of integrity. This commitment underscores our philosophy of “doing well by doing good,” every day.
Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM
Ophthalmology. 2014 Nov;121(11):2247-54.
YOU ARE NOW LEAVING REGENERON.COM.
Thank you for reaching out to us. We'll be in touch soon.
The websites regeneron.com and regeneron.ie (the "Regeneron Sites") use "cookies". Cookies are small text files which are automatically placed on your computer by the internet browser when you visit the Sites. A cookie can, amongst other things, track the web pages you visit and the options you use. Regeneron Pharmaceuticals, Inc. and its affiliates, Regeneron Ireland Unlimited Company and Regeneron UK Limited (together, "Regeneron", "we", "us" or "our") use this data to make the Sites more user-friendly and efficient. We use Google Analytics cookie service to track and obtain reports on how visitors are using the Sites. The information obtained with this cookie, which includes the IP address of your computer, will be transmitted to and stored by Google on servers in the United States. Google may share that information with third parties if Google is obliged to do so by law or to the extent such third parties are processing this information on behalf of Google. Regeneron has no influence on such use.